Details
Stereochemistry | ACHIRAL |
Molecular Formula | 3I.In |
Molecular Weight | 495.531 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[In+3].[I-].[I-].[I-]
InChI
InChIKey=RMUKCGUDVKEQPL-UHFFFAOYSA-K
InChI=1S/3HI.In/h3*1H;/q;;;+3/p-3
Indium is a rare, soft silvery-white metal. It is used in some manufacturing process, butt here is no known biological role for indium in the human body.
Although there are claims that indium increases hormone production, stimulates immune system function, and increases energy, there is no reliable scientific evidence to support such claims.
In vitro, indium-III salts appears to have cytotoxic activity against melanoma. Indium cation (Indium-III), when complexed with 8-hydroxyquinoline (oxine), has been employed as a radioactive platelet label for thrombus imaging in animals and man. The short half-life (2.8 d) and high yield of gamma photons of 111In make it ideal for in vitro counting and external imaging. Indium In 111 ProstaScint (Capromab Pendetide) is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (eg chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated for patients who are not at high risk. Indium In 111 ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0042168 Sources: https://www.ncbi.nlm.nih.gov/pubmed/473213 |
|||
Target ID: P06214 Gene ID: 25374.0 Gene Symbol: Alad Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7084431 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Indium In 111 Chloride Approved UseIndium In 111 Chloride Sterile Solution is indicated for radiolabeling OncoScint CR/OV or ProstaScint
preparations used for in vivo diagnostic imaging procedures. It is also indicated for radiolabeling
Zevalin preparations used for Radioimmunotherapy procedures. Please refer to the package insert for OncoScint CR/OV, ProstaScint or Zevalin for information on the final drug product.
Indium In 111 ProstaScint (Capromab Pendetide) is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (eg chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated for patients who are not at high risk.
Indium In 111 ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium In 111 ProstaScint following radiation therapy has not been studied. Launch Date1996 |
PubMed
Title | Date | PubMed |
---|---|---|
New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts. | 1992 Apr |
|
Preparation of indium-115-labeled diethylenetriaminetetraacetic acid monoacetamide peptides purified by 8-hydroxyquinoline. | 2000 Dec 1 |
|
Effect of Metalation on Porphyrin-Based Bifunctional Agents in Tumor Imaging and Photodynamic Therapy. | 2016 Mar 16 |
|
Synthesis and opioid receptor binding of indium (III) and [(111)In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors. | 2016 Oct 6 |
Sample Use Guides
Indium In 111 ProstaScint (Capromab Pendetide) has been
administered in single doses to over 600 patients in clinical studies,
and in repeat administrations (2 to 4 infusions) to 61 patients. A 0.5 mg dose was determined to be the lowest effective dose.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12191877
One million alveolar macrophages obtained from hamsters were exposed to 60 ug of ferrosoferric oxide and 2, 4, 10 and 20 ug of Indium arsenide (InAs) particles.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3Y156GSM7E
Created by
admin on Fri Dec 15 19:51:39 GMT 2023 , Edited by admin on Fri Dec 15 19:51:39 GMT 2023
|
PRIMARY | |||
|
Indium(III) iodide
Created by
admin on Fri Dec 15 19:51:39 GMT 2023 , Edited by admin on Fri Dec 15 19:51:39 GMT 2023
|
PRIMARY | |||
|
83539
Created by
admin on Fri Dec 15 19:51:39 GMT 2023 , Edited by admin on Fri Dec 15 19:51:39 GMT 2023
|
PRIMARY | |||
|
236-839-6
Created by
admin on Fri Dec 15 19:51:39 GMT 2023 , Edited by admin on Fri Dec 15 19:51:39 GMT 2023
|
PRIMARY | |||
|
13510-35-5
Created by
admin on Fri Dec 15 19:51:39 GMT 2023 , Edited by admin on Fri Dec 15 19:51:39 GMT 2023
|
PRIMARY | |||
|
DTXSID5065516
Created by
admin on Fri Dec 15 19:51:39 GMT 2023 , Edited by admin on Fri Dec 15 19:51:39 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD